Back to Search
CHRISTINA TOPHAM, MD
MD
Dermatology Physician
NPI: 1316575319IndividualAccepts Medicare
Specialties, Licenses & Credentials
Dermatology PhysicianPrimary
Dermatology
Code: 207N00000X
12439716-1205(UT)
CMS Specialties
PrimaryDERMATOLOGY
Education
UNIVERSITY OF UTAH SCHOOL OF MEDICINE
Class of 2020
Research & Publications (20)
Orientation preferences of backbone secondary amide functional groups in peptide nucleic acid complexes: quantum chemical calculations reveal an intrinsic preference of cationic D-amino acid-based chiral PNA analogues for the P-form.
PMID 17071666·Biophys J·2007
8-other
On the spatial disposition of the fifth transmembrane helix and the structural integrity of the transmembrane binding site in the opioid and ORL1 G protein-coupled receptor family.
PMID 10906343·Protein Eng·2000
8-other
The kinetic basis of a general method for the investigation of active site content of enzymes and catalytic antibodies: first-order behaviour under single-turnover and cycling conditions.
PMID 10887904·J Theor Biol·2000
7-preclinical
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
PMID 19451431·J Clin Oncol·2009
3-trial
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
PMID 19451425·J Clin Oncol·2009
3-trial
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
PMID 17630037·Lancet·2007
4-observational
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
PMID 17194911·J Clin Oncol·2007
3-trial
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.
PMID 16622464·Br J Cancer·2006
3-trial
Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients.
PMID 16391786·Int J Oncol·2006
8-other
Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins.
PMID 16015034·Oncology·2005
6-review
Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer.
PMID 16010411·Int J Oncol·2005
4-observational
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
PMID 15365570·Br J Cancer·2004
3-trial
A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer.
PMID 15284252·J Clin Oncol·2004
3-trial
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
PMID 15175436·N Engl J Med·2004
3-trial
The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters.
PMID 14719098·Int J Oncol·2004
8-other
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.
PMID 12583944·Lancet·2003
3-trial
Oncosurgery: a new reality in metastatic colorectal carcinoma.
PMID 12422303·Semin Oncol·2002
6-review
Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa.
PMID 11847938·Ann Pharmacother·2002
3-trial
Kinetic and titration methods for determination of active site contents of enzyme and catalytic antibody preparations.
PMID 11384190·Methods·2001
8-other
The nociceptin (ORL1) receptor: molecular cloning and functional architecture.
PMID 10998522·Peptides·2000
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 30 N 1900 E RM 4A330
SALT LAKE CITY, UT 84132 - Phone
- (801) 581-6465
Quick Facts
- NPI
- 1316575319
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 6
- Publications
- 20
Are you this provider?
Claim Your Profile